NCT00216762View on ClinicalTrials.gov

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Urticaria

Interventions

DRUG

Rituximab

Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart

Trial Locations (1)

21224

Johns Hopkins University, Bayview Medical Center, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER